Neurology >
General Neurology
News, opinions and meeting coverage in neurology.
Generic Copaxone for MS Passes Clinical Test
BOSTON -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it to win regulatory approval as a generic drug.
Sep 12, 2014
Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry
BOSTON -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.
Sep 12, 2014
CCSVI Practices Suboptimal but Patients Don't Mind
DALLAS -- Canadian multiple sclerosis patients who left the country to undergo the controversial procedure called chronic cerebrospinal venous insufficiency (CCSVI) often received poor pre- and postoperative care, but most were still relatively satisfied overall, a researcher reported here.
Jun 01, 2014
Gastro Effects Dog Oral MS Drug Tecfidera
DALLAS -- Large proportions of patients starting on dimethyl fumarate (Tecfidera) for multiple sclerosis need additional medications to manage the drug's GI and other side effects, and a substantial minority ultimately find the drug intolerable.
May 30, 2014
Medtronic's Infuse Moves From Operating Room to Courtroom
An investigative series by 51˶/Milwaukee Journal Sentinel has been tracking the spinal fusion device called Infuse in a 4-year-long series and now reports how a flawed FDA system for device approval may have led to a long string of adverse events culminating in thousands of liability suits.
May 18, 2014
Pay and Practice: Are Neurologists Primary Care Docs?
WASHINGTON -- Neurology isn't often mentioned in the same breath as primary care, but the American Academy of Neurology is again lobbying to gain that sobriquet -- this time to take advantage of a recent policy change that benefits primary care providers.
Jan 15, 2014
Droxidopa for OH Slammed by FDA Reviewers
SILVER SPRING, Md. -- Droxidopa (Northera) is getting a second look by an FDA advisory committee for the treatment of orthostatic hypotension stemming from neurological disorders like Parkinson's disease, but an agency review doesn't look promising for approval.
Jan 13, 2014
Killing Pain: Tramadol the 'Safe' Drug of Abuse
Almost 2 decades have passed since the FDA approved tramadol as a 'safe' opioid, but the intervening years provide evidence to question that 'safe' claim, as this latest investigation by John Fauber for the Milwaukee Journal Sentinel-51˶ revealed.
Dec 22, 2013